Spero Therapeutics Stock Falls 21%, Cuts Jobs, Suspends Pulmonary Treatment Development Program

Dow Jones

Oct 30, 2024

By Paul Ziobro

Shares of Spero Therapeutics plunged after the company said it was suspending the development of a program for a lung infection treatment and cutting 39% of jobs to preserve cash.

The stock fell 21.4% to $1.03 in late trading, after closing the regular trading session at $1.31. Through Tuesday's close, the stock had been down 10.9% this year.

The Cambridge, Mass.-based biopharmaceutical company said it would restructure after an interim analysis of a study of SPR720, a treatment for non-tuberculous mycobacterial-pulmonary disease, failed to meet its primary endpoint.

The company decided to suspend the current development program and will look at other potential paths forward as the remaining data are collected and analyzed.

Spero said the restructuring and layoffs will extend its cash runway and support operations into mid-2026.

Write to Paul Ziobro at paul.ziobro@wsj.com

(END) Dow Jones Newswires

October 29, 2024 17:15 ET (21:15 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2479682312"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2479682312\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2479682312?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 05:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479682312","market":"nz","top_or_hot":-1,"title":"Spero Therapeutics Stock Falls 21%, Cuts Jobs, Suspends Pulmonary Treatment Development Program","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Paul Ziobro \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Spero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> plunged after the company said it was suspending the development of a program for a lung infection treatment and cutting 39% of jobs to preserve cash. \n</p>\n<p>\n  The stock fell 21.4% to $1.03 in late trading, after closing the regular trading session at $1.31. Through Tuesday's close, the stock had been down 10.9% this year. \n</p>\n<p>\n  The Cambridge, Mass.-based biopharmaceutical company said it would restructure after an interim analysis of a study of SPR720, a treatment for non-tuberculous mycobacterial-pulmonary disease, failed to meet its primary endpoint. \n</p>\n<p>\n  The company decided to suspend the current development program and will look at other potential paths forward as the remaining data are collected and analyzed. \n</p>\n<p>\n  Spero said the restructuring and layoffs will extend its cash runway and support operations into mid-2026. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 29, 2024 17:15 ET (21:15 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Spero Therapeutics Stock Falls 21%, Cuts Jobs, Suspends Pulmonary Treatment Development Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpero Therapeutics Stock Falls 21%, Cuts Jobs, Suspends Pulmonary Treatment Development Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-10-30 05:15</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Paul Ziobro \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Spero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> plunged after the company said it was suspending the development of a program for a lung infection treatment and cutting 39% of jobs to preserve cash. \n</p>\n<p>\n  The stock fell 21.4% to $1.03 in late trading, after closing the regular trading session at $1.31. Through Tuesday's close, the stock had been down 10.9% this year. \n</p>\n<p>\n  The Cambridge, Mass.-based biopharmaceutical company said it would restructure after an interim analysis of a study of SPR720, a treatment for non-tuberculous mycobacterial-pulmonary disease, failed to meet its primary endpoint. \n</p>\n<p>\n  The company decided to suspend the current development program and will look at other potential paths forward as the remaining data are collected and analyzed. \n</p>\n<p>\n  Spero said the restructuring and layoffs will extend its cash runway and support operations into mid-2026. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 29, 2024 17:15 ET (21:15 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2479682312","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479682312","pubTimestamp":1730236500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Spero Therapeutics plunged after the company said it was suspending the development of a program for a lung infection treatment and cutting 39% of jobs to preserve cash.The stock fell 21.4% to $1.03 in late trading, after closing the regular trading session at $1.31. Through Tuesday's close, the stock had been down 10.9% this year.The Cambridge, Mass.-based biopharmaceutical company said it would restructure after an interim analysis of a study of SPR720, a treatment for non-tuberculous mycobacterial-pulmonary disease, failed to meet its primary endpoint.The company decided to suspend the current development program and will look at other potential paths forward as the remaining data are collected and analyzed.Spero said the restructuring and layoffs will extend its cash runway and support operations into mid-2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LENZ":"Therapeutics","SPRO":"Spero Therapeutics Inc."},"translate_title":"Spero Therapeutics股价下跌21%，裁员，暂停肺部治疗开发计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRO":0.9,"LENZ":1},"content_text":"By Paul Ziobro \n\n\n \n\n\n  Shares of Spero Therapeutics plunged after the company said it was suspending the development of a program for a lung infection treatment and cutting 39% of jobs to preserve cash. \n\n\n  The stock fell 21.4% to $1.03 in late trading, after closing the regular trading session at $1.31. Through Tuesday's close, the stock had been down 10.9% this year. \n\n\n  The Cambridge, Mass.-based biopharmaceutical company said it would restructure after an interim analysis of a study of SPR720, a treatment for non-tuberculous mycobacterial-pulmonary disease, failed to meet its primary endpoint. \n\n\n  The company decided to suspend the current development program and will look at other potential paths forward as the remaining data are collected and analyzed. \n\n\n  Spero said the restructuring and layoffs will extend its cash runway and support operations into mid-2026. \n\n\n \n\n\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 29, 2024 17:15 ET (21:15 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}